{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"pt must have at least 8 weeks of treatment to receive MRI scan, scans are every other cycle (every 2 months). Response measured by a bidimensionally measured leison and clearly defined margins by CT or MRI scan.\n\nComplete Response (CR): complete disappearance of all measurable and evaluable disease. No new lesions, not on any steroids Partial Response (PR): \\>= 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Steriod dose must be no greater than max used in 1st 8wks of therapy Stable: not qualify for CR, PR, or progression. Steriod dose must be no greater than max used in 1st 8wks of therapy Progression (PD): 25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening or failure to return for evalution due to death or deteriorating condition (unless clearly unrelated to brain cancer).","groups":[{"description":"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.\n\nerlotinib: Given orally\n\ntemsirolimus: Given IV","id":"OG000","title":"Phase I 15mg Temsirolimus (MTD Dose)"}],"paramType":"NUMBER","populationDescription":"Response was reviewed only in those patients treated at the MTD (15mg temsirolimus)","reportingStatus":"POSTED","timeFrame":"at least 8 weeks of treatment","title":"Efficacy - Response Phase 1","type":"PRIMARY","unitOfMeasure":"participants"}